Formulary Update October 2023

The following changes to the <u>Adult Medicines Formulary</u> have been agreed during the ADTC or sub-committee meetings since May 2023. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed here

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Daktacort ointment		13.4.2	discontinued
Sunsense Ultra		13.8.1.1	discontinued
Pholcodine linctus		3.9.1	MHRA safety advice
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Prasugrel	Prasugrel is restricted to specialist initiation and use in combination with aspirin for patients after percutaneous coronary intervention (PCI) in accordance with NHSGGGGUID Guidelines for Antiplatelet Therapy in the Secondary Prevention of Coronary Heart Disease.	s C	Formulary appeal
Enerzair	Maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta <sub>2</sub> -agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.	3.2.2 Total Formulary	Formulary appeal
Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Salbutamol MDI inhaler	Moved from Preferred List to Total Formulary	3.1.1.1.1	Formulary appeal
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Enoxaparin	Generic prescribing in acute services no longer recommended (previous brand switch now completed).  All sectors should prescribe by brand.	2.8.1	Formulary housekeeping
Lacosamide	Brand name removed as now generically available and listed on Scottish Drug Tariff	4.8.1	Formulary housekeeping